{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:39:50Z","timestamp":1790998790047,"version":"4.1.0"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic associated fatty liver disease (MAFLD) is a novel terminology introduced in 2020 to provide a more accurate description of fatty liver disease associated with metabolic dysfunction. It replaces the outdated term nonalcoholic fatty liver disease (NAFLD) and aims to improve diagnostic criteria and tailored treatment strategies for the disease. NAFLD, the most prevalent liver disease in western industrialized nations, has been steadily increasing in prevalence and is associated with serious complications such as cirrhosis and hepatocellular carcinoma. It is also linked to insulin resistance syndrome and cardiovascular diseases. However, current studies on NAFLD have limitations in meeting necessary histological endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This literature review aims to consolidate recent knowledge and discoveries concerning MAFLD, integrating the diverse aspects of the disease. Specifically, it focuses on analyzing the diagnostic criteria for MAFLD, differentiating it from NAFLD and alcoholic fatty liver disease (AFLD), and exploring the epidemiology, clinical manifestations, pathogenesis, and management approaches associated with MAFLD. The review also explores the associations between MAFLD and other conditions. It discusses the heightened mortality risk associated with MAFLD and its link to chronic kidney disease (CKD), showing that MAFLD exhibits enhanced diagnostic accuracy for identifying patients with CKD compared to NAFLD. The association between MAFLD and incident\/prevalent CKD is supported by cohort studies and meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This literature review highlights the importance of MAFLD as a distinct terminology for fatty liver disease associated with metabolic dysfunction. The review provides insights into the diagnostic criteria, associations with CKD, and management approaches for MAFLD. Further research is needed to develop more accurate diagnostic tools for advanced fibrosis in MAFLD and to explore the underlying mechanisms linking MAFLD with other conditions. This review serves as a valuable resource for researchers and healthcare professionals seeking a comprehensive understanding of MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1291501","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T06:19:53Z","timestamp":1705990793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":114,"title":["Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Mohammad","family":"Habibullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaleed","family":"Jemmieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Ouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Zulqurnain","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Imad","family":"Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Naser","family":"Elzouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4254\/wjh.v15.i2.123","article-title":"Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate","volume":"15","author":"Fouad","year":"2023","journal-title":"World J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What's in a name? Renaming 'NAFLD' to 'MAFLD'","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-126-2-199701150-00008","article-title":"Nonalcoholic steatohepatitis","volume":"126","author":"Sheth","year":"1997","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1055\/s-2001-12926","article-title":"Clinical features and natural history of nonalcoholic steatosis syndromes","volume":"21","author":"Falck-Ytter","year":"2001","journal-title":"Semin Liver Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","article-title":"Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999\u20132016","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","article-title":"Trends in the prevalence of metabolic dysfunction\u2013associated fatty liver disease in the United States, 2011\u20132018","volume":"20","author":"Wong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","article-title":"The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease\u2013related genetic variants","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(21)00275-2","article-title":"Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa","volume":"6","author":"Spearman","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e000780","DOI":"10.1136\/bmjgast-2021-000780","article-title":"Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt","volume":"8","author":"Tomah","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\"","volume":"24","author":"Fang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3978\/j.issn.2304-3881.2014.11.05","article-title":"Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction","volume":"4","author":"Basaranoglu","year":"2015","journal-title":"Hepatobil Surg Nutr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"R1319","DOI":"10.1152\/ajpregu.1996.271.5.R1319","article-title":"Changes in insulin action, triglycerides, and lipid composition during sucrose feeding in rats","volume":"271","author":"Pagliassotti","year":"1996","journal-title":"Am J Phys"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"R1334","DOI":"10.1152\/ajpregu.2000.279.4.R1334","article-title":"Comparison of the effects of sucrose and fructose on insulin action and glucose tolerance","volume":"279","author":"Thresher","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/jn\/130.6.1531","article-title":"A high fructose diet affects the early steps of insulin action in muscle and liver of rats","volume":"130","author":"Bezerra","year":"2000","journal-title":"J Nutr"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jnutbio.2013.10.014","article-title":"Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats","volume":"25","author":"Rebollo","year":"2014","journal-title":"J Nutr Biochem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/10715762.2014.997229","article-title":"Endoplasmic reticulum stress and Nrf2 repression in circulating cells of type 2 diabetic patients without the recommended glycemic goals","volume":"49","author":"Mozzini","year":"2015","journal-title":"Free Radic Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.metabol.2015.02.003","article-title":"Endoplasmic reticulum stress response in non-alcoholic steatohepatitis: the possible role of physical exercise","volume":"64","author":"Passos","year":"2015","journal-title":"Metabolism"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3109\/10715762.2015.1078461","article-title":"Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease","volume":"49","author":"Ashraf","year":"2015","journal-title":"Free Radic Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e30816","DOI":"10.1371\/journal.pone.0030816","article-title":"Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance","volume":"7","author":"Ren","year":"2012","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/db12-1397","article-title":"Activation of PPAR\u03b1 ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress","volume":"62","author":"Chan","year":"2013","journal-title":"Diabetes"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.toxlet.2012.06.002","article-title":"Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice","volume":"212","author":"Zhang","year":"2012","journal-title":"Toxicol Lett"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1476-511X-10-122","article-title":"Effect of \u03b1-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes","volume":"10","author":"Zhang","year":"2011","journal-title":"Lipids Health Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3945\/ajcn.114.094730","article-title":"Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein","volume":"101","author":"Lindeboom","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00125-013-2913-1","article-title":"Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding","volume":"56","author":"Turner","year":"2013","journal-title":"Diabetologia"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"51664","DOI":"10.1074\/jbc.M309377200","article-title":"Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene","volume":"278","author":"Newberry","year":"2003","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1055\/s-0030-1267186","article-title":"A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis","volume":"42","author":"Auinger","year":"2010","journal-title":"Horm Metab Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"Koonen","year":"2007","journal-title":"Diabetes"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-3-030-78315-0_17","article-title":"Bilirubin: a ligand of the PPAR\u03b1 nuclear receptor","volume-title":"Nuclear receptors: The art and science of modulator design and discovery","author":"Hong","year":"2021"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol Rev Camb Philos Soc"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e31812","DOI":"10.1371\/journal.pone.0031812","article-title":"Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass","volume":"7","author":"Knebel","year":"2012","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"587189","DOI":"10.3389\/fendo.2020.587189","article-title":"ChREBP-mediated regulation of lipid metabolism: involvement of the gut microbiota, liver, and adipose tissue","volume":"11","author":"Iizuka","year":"2020","journal-title":"Front Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/db06-0200","article-title":"Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in Ob\/Ob mice","volume":"55","author":"Dentin","year":"2006","journal-title":"Diabetes"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1172\/jci.insight.93626","article-title":"Peroxisomal \u03b2-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease","volume":"3","author":"Moreno-Fernandez","year":"2018","journal-title":"JCI Insight"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1152\/ajpendo.00396.2016","article-title":"Mice with hyperbilirubinemia due to Gilbert\u2019s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPAR\u03b1","volume":"312","author":"Hinds","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","article-title":"Loss of hepatic PPAR\u03b1 promotes inflammation and serum hyperlipidemia in diet-induced obesity","volume":"317","author":"Stec","year":"2019","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1172\/JCI32752","article-title":"Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents","volume":"118","author":"Ota","year":"2008","journal-title":"J Clin Invest"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.celrep.2018.03.109","article-title":"Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages","volume":"23","author":"Krishnan","year":"2018","journal-title":"Cell Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jgh.15746","article-title":"The microbial metabolome in metabolic-associated fatty liver disease","volume":"37","author":"Li","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1888673","article-title":"Links between gut microbiome composition and fatty liver disease in a large population sample","volume":"13","author":"Ruuskanen","year":"2021","journal-title":"Gut Microbes"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.3390\/ijms24054855","article-title":"Fecal metagenomics and metabolomics identifying microbial signatures in non-alcoholic fatty liver disease","volume":"24","author":"Pekkala","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"204201882211321","DOI":"10.1177\/20420188221132138","article-title":"Update on genetics and epigenetics in metabolic associated fatty liver disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and Management of Nonalcoholic Fatty Liver Disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.3350\/cmh.2022.0362","article-title":"Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: current and future developments","volume":"29","author":"Ahn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1155\/2014\/757929","article-title":"Biomarkers in nonalcoholic fatty liver disease","volume":"28","author":"Neuman","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3350\/cmh.2017.0042","article-title":"Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eprac.2022.03.016","article-title":"Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A Meta-analysis and systematic review of 12\u202f620\u202f736 individuals","volume":"28","author":"Quek","year":"2022","journal-title":"Endocr Pract"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metab Clin Exp"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jdi.13678","article-title":"Metabolic associated fatty liver disease is a risk factor for chronic kidney disease","volume":"13","author":"Hashimoto","year":"2022","journal-title":"J Diabetes Invest"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"101344","DOI":"10.1016\/j.diabet.2022.101344","article-title":"Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: a nationwide cohort study","volume":"48","author":"Jung","year":"2022","journal-title":"Diabetes Metab"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ndt\/gfac188","article-title":"Metabolic dysfunction\u2013associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease","volume":"38","author":"Tanaka","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","article-title":"Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups","volume":"42","author":"Ayada","year":"2022","journal-title":"Liver Int"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metab Clin Exp"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy","volume":"134","author":"Xian","year":"2021","journal-title":"Chin Med J"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a Nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.3389\/fendo.2022.934225","article-title":"Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis","volume":"13","author":"Wen","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.3390\/ijms22115462","article-title":"Non-obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study","volume":"22","author":"Fukunaga","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12944-022-01659-1","article-title":"Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis","volume":"21","author":"Zeng","year":"2022","journal-title":"Lipids Health Dis"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3389\/fendo.2022.968766","article-title":"Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"761538","DOI":"10.3389\/fmed.2021.761538","article-title":"Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies","volume":"8","author":"Qu","year":"2021","journal-title":"Front Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of Weight Loss Interventions with Changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and Meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"802","DOI":"10.4093\/dmj.2020.0258","article-title":"Comprehensive review of current and upcoming anti-obesity drugs","volume":"44","author":"Son","year":"2020","journal-title":"Diabetes Metab J"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/MCG.0b013e31824cf51e","article-title":"The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease","volume":"46","author":"Mouzaki","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3390\/nu11122878","article-title":"Dietary patterns and components in nonalcoholic fatty liver disease (NAFLD): what key messages can health care providers offer?","volume":"11","author":"Riazi","year":"2019","journal-title":"Nutrients"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/nu13082649","article-title":"Bariatric surgery and liver disease: general considerations and role of the gut\u2013liver axis","volume":"13","author":"Cerreto","year":"2021","journal-title":"Nutrients"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/ph14030215","article-title":"The evaluation of drug delivery nanocarrier development and pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): an update","volume":"14","author":"Abou Assi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"FC06","DOI":"10.7860\/JCDR\/2017\/28418.10193","article-title":"Comparison of pioglitazone and metformin efficacy against glucocorticoid induced atherosclerosis and hepatic steatosis in insulin resistant rats","volume":"11","author":"Nayak","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","article-title":"Antidiabetic drugs and statins in nonalcoholic fatty liver disease","volume":"9","author":"Kothari","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"10446","DOI":"10.7759\/cureus.10446","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/liv.14116","article-title":"Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study","volume":"39","author":"van den Berg","year":"2019","journal-title":"Liver Int"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.3390\/nu12113302","article-title":"Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update","volume":"12","author":"Barchetta","year":"2020","journal-title":"Nutrients"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1039\/D0FO01095B","article-title":"Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Guo","year":"2020","journal-title":"Food Funct"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1507\/endocrj.EJ20-0758","article-title":"Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)\u2014\u200da \u200dpopulation-based study","volume":"68","author":"Wan","year":"2021","journal-title":"Endocr J"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"175628482097491","DOI":"10.1177\/1756284820974917","article-title":"The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"13","author":"Abdel-Maboud","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/17474124.2020.1817740","article-title":"Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?","volume":"15","author":"Kj\u00e6r","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2213-8587(22)00074-2","article-title":"Tirzepatide adds hepatoprotection to its armoury","volume":"10","author":"Targher","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"213","DOI":"10.20524\/aog.2022.0704","article-title":"Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis","volume":"35","author":"Sinakos","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.freeradbiomed.2021.10.017","article-title":"Role of vitamin E in the treatment of non-alcoholic steatohepatitis","volume":"177","author":"Sumida","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"key":"ref116","first-page":"293","article-title":"Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?","volume":"21","author":"Finelli","year":"2012","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front Biosci"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","article-title":"Evolution of NAFLD and its management","volume":"35","author":"Mundi","year":"2020","journal-title":"Nutr Clin Pract"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3748\/wjg.v20.i15.4382","article-title":"Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial","volume":"20","author":"Zelber-Sagi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur J Sport Sci"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2019.11.015","article-title":"Physical exercise and liver \"fitness\": role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease","volume":"32","author":"Stevanovi\u0107","year":"2020","journal-title":"Mol Metab"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/hep.26393","article-title":"Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial)","volume":"58","author":"Bacchi","year":"2013","journal-title":"Hepatology"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1210\/jc.2004-1983","article-title":"Dietary fat content modifies liver fat in overweight nondiabetic subjects","volume":"90","author":"Westerbacka","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.3389\/fmed.2025.1704750","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1291501\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:09:05Z","timestamp":1759331345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1291501\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":126,"alternative-id":["10.3389\/fmed.2024.1291501"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1291501","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"article-number":"1291501"}}